Shanghai Haohai Biological Technology Co Ltd
SSE:688366

Watchlist Manager
Shanghai Haohai Biological Technology Co Ltd Logo
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Watchlist
Price: 53.32 CNY 2.24% Market Closed
Market Cap: 12.4B CNY

EV/EBITDA
Enterprise Value to EBITDA

24.1
Current
54.3
Median
4.1
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
24.1
=
Enterprise Value
9.9B CNY
/
EBITDA
411.2m CNY
EBITDA Growth EV/EBITDA to Growth
CN
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Average EV/EBITDA: 16.5
24.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 033.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.8 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.3
11%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -662.7 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
12.2
2-Years Forward
EV/EBITDA
10.8
3-Years Forward
EV/EBITDA
N/A